204 related articles for article (PubMed ID: 16750673)
21. Maintenance therapy in lymphoma.
Mihelic R; Kaufman J; Lonial S; Flowers C
Clin Lymphoma Myeloma; 2007 Sep; 7(8):507-13. PubMed ID: 18021467
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
[TBL] [Abstract][Full Text] [Related]
23. Rituximab for the treatment of follicular lymphoma.
Cheah CY; Lingaratnam S; Seymour JF
Future Oncol; 2013 Sep; 9(9):1283-98. PubMed ID: 23980675
[TBL] [Abstract][Full Text] [Related]
24. [Cost-effectiveness analysis of maintenance therapy with rituximab in patients with follicular lymphoma responding to induction therapy at the first line].
Castro Gómez AJ; López-Guillermo A; Rueda Domínguez A; Salar A; Varela Moreno C; Rubio-Terrés C
Rev Esp Salud Publica; 2012; 86(2):163-76. PubMed ID: 22991059
[TBL] [Abstract][Full Text] [Related]
25. Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies.
Nabhan C; Smith SM; Kahl BS
Leuk Lymphoma; 2012 May; 53(5):770-8. PubMed ID: 21958083
[TBL] [Abstract][Full Text] [Related]
26. New treatment approaches to indolent non-Hodgkin's lymphoma.
Seymour JF
Semin Oncol; 2004 Feb; 31(1 Suppl 2):27-32. PubMed ID: 15042532
[TBL] [Abstract][Full Text] [Related]
27. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Litchy S; Shaffer DW; Lackey VL; Grimaldi M; Greco FA
J Clin Oncol; 2005 Feb; 23(6):1088-95. PubMed ID: 15657401
[TBL] [Abstract][Full Text] [Related]
28. Maintenance therapy in follicular lymphoma.
Michallet AS; Coiffier B; Salles G
Curr Opin Oncol; 2011 Sep; 23(5):449-54. PubMed ID: 21734580
[TBL] [Abstract][Full Text] [Related]
29. Optimization of postremission therapy in follicular lymphoma: efficacy of rituximab maintenance.
Roy R; Gordon LI
J Natl Compr Canc Netw; 2011 May; 9(5):563-71. PubMed ID: 21550969
[TBL] [Abstract][Full Text] [Related]
30. 'Watch and wait' as initial management for patients with follicular lymphomas: still a viable strategy?
Hagemeister FB
BioDrugs; 2012 Dec; 26(6):363-76. PubMed ID: 23057946
[TBL] [Abstract][Full Text] [Related]
31. Rituximab maintenance therapy in follicular lymphoma.
Forstpointner R; Dreyling M
Curr Hematol Malig Rep; 2007 Oct; 2(4):213-8. PubMed ID: 20425372
[TBL] [Abstract][Full Text] [Related]
32. Increasing treatment options in indolent non-Hodgkin's lymphoma.
Solal-Céligny P
Semin Oncol; 2002 Apr; 29(2 Suppl 6):2-6. PubMed ID: 12040527
[TBL] [Abstract][Full Text] [Related]
33. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.
Hainsworth JD; Litchy S; Burris HA; Scullin DC; Corso SW; Yardley DA; Morrissey L; Greco FA
J Clin Oncol; 2002 Oct; 20(20):4261-7. PubMed ID: 12377971
[TBL] [Abstract][Full Text] [Related]
34. A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas.
Nabhan C; Ollberding NJ; Villines D; Chiu BC; Caces DB; Valdez TV; Ghielmini M; Hsu Schmitz SF; Smith SM
Leuk Lymphoma; 2014 Jun; 55(6):1288-94. PubMed ID: 23998254
[TBL] [Abstract][Full Text] [Related]
35. Primary duodenal follicular lymphoma successfully treated with rituximab.
Aguiar-Bujanda D; Quiñones-Morales I; Camacho-Galán R; Llorca-Martínez I; Rivero-Vera JC; Bohn-Sarmiento U; Aguiar-Morales J
Clin Transl Oncol; 2007 Jul; 9(7):471-2. PubMed ID: 17652063
[TBL] [Abstract][Full Text] [Related]
36. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial.
Hainsworth JD
Semin Oncol; 2002 Feb; 29(1 Suppl 2):25-9. PubMed ID: 11842385
[TBL] [Abstract][Full Text] [Related]
37. Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival.
Turturro F
Expert Rev Anticancer Ther; 2007 Jul; 7(7):959-65. PubMed ID: 17627454
[TBL] [Abstract][Full Text] [Related]
38. Clearing minimal residual disease with rituximab consolidation therapy.
Brugger W
Semin Oncol; 2004 Feb; 31(1 Suppl 2):33-7. PubMed ID: 15042533
[TBL] [Abstract][Full Text] [Related]
39. Rituximab maintenance therapy for follicular lymphoma.
Haines I
Lancet; 2011 Apr; 377(9772):1151; author reply 1151-2. PubMed ID: 21459205
[No Abstract] [Full Text] [Related]
40. Maintenance therapy for low-grade lymphomas: has the time come?
Cartron G; Solal-Céligny P
Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
